The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
about
Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled TrialsThe Effects of a Gentle Yoga Program on Sleep, Mood, and Blood Pressure in Older Women with Restless Legs Syndrome (RLS): A Preliminary Randomized Controlled Trial.The effects of meditation on perceived stress and related indices of psychological status and sympathetic activation in persons with Alzheimer's disease and their caregivers: a pilot study.Repeated sleep restriction in rats leads to homeostatic and allostatic responses during recovery sleep.Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patientsPredictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin.Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling.Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)Hypoglycaemia in Type 2 diabetes.Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.Pioglitazone and sulfonylureas: effectively treating type 2 diabetesPharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.Investigating the Burden of Chronic Pain: An Inflammatory and Metabolic CompositeClinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsEffectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.Sleep loss as a factor to induce cellular and molecular inflammatory variations.Clinical efficacy of a medically supervised outpatient high-protein, low-calorie diet program is equivalent in prediabetic, diabetic and normoglycemic obese patientsRole of K(ATP) channels in β-cell resistance to oxidative stress.The importance of synthetic drugs for type 2 diabetes drug discovery.Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.New insights into antidiabetic drugs: Possible applications in cancer treatment.Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.Effects of Extract from Solid-State Fermented Cordyceps sinensis on Type 2 Diabetes Mellitus.Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial.Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, plEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.The GeneTrawler: mapping potential drug targets in human and rat tissues.Effects of sleep deprivation on brain bioenergetics, sleep, and cognitive performance in cocaine-dependent individuals.A Portulaca oleracea L. extract promotes insulin secretion via a K+ATP channel dependent pathway in INS-1 pancreatic β-cells.
P2860
Q26770719-DCAC29D9-9FE0-475B-AAA8-C7AF3F199A15Q30427506-FDC1BABA-75FB-4B85-B90B-BB0BCC9D906AQ30427719-D4985309-27E9-4AB6-AF03-07B4EEBECFF8Q30479547-B941F4CF-8B7E-46D6-B6D0-EF56092A46A0Q33587806-D8BB05D6-2F2A-4411-8A50-53A55C213C16Q33628631-A064726F-E3BB-47B4-BA53-5FFA5D7D4D4DQ33714751-A70D4792-2039-4C65-9AE5-2105171FEF14Q33813015-7667F2A1-E040-4AE5-A557-910A0AFB638FQ34264359-E987250F-28A2-41CE-87F0-C1D4150252EDQ34739954-83385896-D5B2-4A23-B3E9-B316D3A1C445Q35260937-89AB2E71-BBFE-4AAC-AB79-A634BD2B27DEQ35659489-57E6C286-E9C2-47BF-BACE-711A4F6EF5DBQ35987456-CF35863E-B7AA-4D9E-BD74-D176740A41BEQ35997284-118CF7EF-B387-4CD3-97C6-306E05BFE506Q36812821-1979FCE9-DC51-45E9-85D4-FCF137173BA4Q36985135-AA8163E7-4B3A-434D-8E76-8CF024D9E3F7Q37009983-5FFDCA6A-FE56-4392-89F9-070CF8EA3CF5Q37011769-2E80C117-7671-43DB-93F7-49E52D6B1EA9Q37257372-EADB2711-3B1A-4198-A984-745A8E342EE7Q37400794-ED3CAB14-7184-4A09-8832-B5C2A46A78B4Q37614461-DE3D69BD-5ED5-4678-9AFC-0C954B1F82D6Q38038657-B8F91947-5334-4E9E-B45E-E82506BA145EQ38139508-D9F8EF88-8E85-45EA-A832-C4AAB0C4E83CQ38270699-559022D0-462E-4395-AB1B-0ACA9DCF828FQ38524435-94AB7139-B172-4246-A9CD-151AF064B6D5Q38780360-F8C7AA1E-3232-4B25-9671-AA0D2BA3FE3DQ38925481-F4EB3F21-E8E2-4F63-9F7A-DC3C744F3029Q39272833-4332F7ED-AF4B-4AE7-AD59-3172CF337DDFQ40148424-445E4E6D-578D-4E8D-A660-1025F1B25327Q41980574-18F93CB1-C162-43BE-B96E-F2CCEE98423CQ43045655-3DD443F9-0DA4-4EA6-ACF1-371BC9D449E6Q43054840-772CB002-E23A-4982-9556-A92544D50B2BQ43826389-994BA159-C3FA-4D4A-90A2-931685273F86Q44067944-F7A1E68D-800B-41B2-A304-5514C7E0EB12Q50067957-20A06D6D-2070-4996-9B43-F2945EFD985FQ51233383-AF3056B6-D307-4492-A6D3-B49D6B06598FQ51468797-BE9EE5FF-DC93-4AE4-A762-2BFAA051A29EQ53575108-8F53EB3A-D1B5-43FD-B237-801784450DFAQ54574256-B08C0214-527D-4983-AB69-FE3DFA2D7D21Q54937165-CFF0DB8F-CD89-4FF8-A9A5-8437DB899A1F
P2860
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
@ast
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
@en
type
label
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
@ast
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
@en
prefLabel
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
@ast
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
@en
P1433
P1476
The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
@en
P2093
Nicolò Pulizzi
Stefano Del Prato
P356
10.1016/J.METABOL.2006.02.003
P433
P577
2006-05-01T00:00:00Z